Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER METABOLISM

Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Loss of Slc7a5 attenuates Kras-driven tumor progression.

References

  1. 1.

    Fearon, E. R. & Vogelstein, B. Cell 61, 759–767 (1990).

    CAS  Article  Google Scholar 

  2. 2.

    The Cancer Genome Atlas Network. Nature 487, 330–337 (2012).

    Article  Google Scholar 

  3. 3.

    Schwitalla, S. et al. Cell 152, 25–38 (2013).

    CAS  Article  Google Scholar 

  4. 4.

    Haigis, K. M. et al. Nat. Genet. 40, 600–608 (2008).

    CAS  Article  Google Scholar 

  5. 5.

    Verissimo, C. S. et al. eLife 5, e18489 (2016).

    Article  Google Scholar 

  6. 6.

    Gimple, R. C. & Wang, X. Front. Oncol. 9, 965 (2019).

    Article  Google Scholar 

  7. 7.

    Kimmelman, A. C. Clin. Cancer Res. 21, 1828–1834 (2015).

    CAS  Article  Google Scholar 

  8. 8.

    Warburg, O. Science 123, 309–314 (1956).

    CAS  Article  Google Scholar 

  9. 9.

    Smith, B. et al. Cell Rep. 17, 821–836 (2016).

    CAS  Article  Google Scholar 

  10. 10.

    Ying, H. et al. Cell 149, 656–670 (2012).

    CAS  Article  Google Scholar 

  11. 11.

    Najumudeen, A. K. et al. Nat. Genet. https://doi.org/10.1038/s41588-020-00753-3 (2020).

  12. 12.

    Guinney, J. et al. Nat. Med. 21, 1350–1356 (2015).

    CAS  Article  Google Scholar 

  13. 13.

    Canon, J. et al. Nature 575, 217–223 (2019).

    CAS  Article  Google Scholar 

  14. 14.

    Hallin, J. et al. Cancer Discov. 10, 54–71 (2020).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Louis Vermeulen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bootsma, S., van Neerven, S.M. & Vermeulen, L. Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. Nat Genet 53, 9–10 (2021). https://doi.org/10.1038/s41588-020-00758-y

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing